|
|
Cowpea Mosaic Virus |
|
Vaxjo ID |
153 |
|
Vaccine Adjuvant Name |
Cowpea Mosaic Virus |
|
Adjuvant VO ID |
VO_0006107
|
|
Description |
A particulate antigen delivery system vaccine adjuvant derived from Cowpea mosaic virus that is able to induce a Th1-biased response |
|
Stage of Development |
Research |
|
Location Licensed |
US (UCSD) |
|
Host Species for Testing |
Mouse |
|
Components |
self-assembling virus like nanoparticles; self assembles into 30 nm icosahedral structures with 60 copies of each small and large coat protein units |
|
Storage |
in buffered solution at 4C or -20 C |
|
Preparation |
empty CPMV VLP system (empty meaning no nucleic acids and non-infectious) produced through molecular farming in plants |
|
Function |
taken up by activated neutrophils as part of anti-tumor immunity |
| References |
Lizotte et al., 2016: Lizotte PH, Wen AM, Sheen MR, Fields J, Rojanasopondist P, Steinmetz NF, Fiering S. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nature nanotechnology. 2016; 11(3); 295-303. [PubMed: 26689376].
|
|
